Last €15.04 EUR
Change Today +0.01 / 0.07%
Volume 16.3K
GLPG On Other Exchanges
As of 8:00 AM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

galapagos nv (GLPG) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/27/14 - €18.42
52 Week Low
10/16/14 - €10.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GALAPAGOS NV (GLPG)

Related News

No related news articles were found.

galapagos nv (GLPG) Related Businessweek News

No Related Businessweek News Found

galapagos nv (GLPG) Details

Galapagos NV, a biotech company, discovers and develops small moleculesfor the treatment of cancer, immuno-inflammatory, osteoarthritis, rheumatoid arthritis, and cystic fibrosis diseases. The company’s products under development include GLPG0634, an orally-available, selective inhibitor of Janus kinase 1 that is in Phase IIB clinical trials for the treatment of rheumatoid arthritis (RA) and potentially other inflammatory diseases; and GLPG0778/555, an investigational compound, which is in Phase II studies for the treatment of lupus, ulcerative colitis, and psoriasis. It is also developing GSK2586184, which is in Phase II clinical trials for the treatment of immuno-inflammatory diseases; GLPG0974, an orally available small molecule that is in Phase IB clinical trials to treat neutrophil-driven inflammatory conditions, such as inflammatory bowel disease; and GLPG1205, a drug candidate that completed Phase I clinical trial for the treatment of inflammatory bowel disease. The company has strategic alliances with GlaxoSmithKline, Janssen Pharmaceutica NV, Servier, and AbbVie; and research collaboration agreement with Calchan Holdings Limited. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

810 Employees
Last Reported Date: 04/25/14
Founded in 1999

galapagos nv (GLPG) Top Compensated Officers

Co-Founder, Chief Executive Officer, Managing...
Total Annual Compensation: €740.1K
Compensation as of Fiscal Year 2013.

galapagos nv (GLPG) Key Developments

Galapagos NV Announces Initiation of the First Phase 1 Study with GLPG1837

Galapagos NV announced the initiation of the first Phase 1 study with GLPG1837. This novel potentiator is designed as a CFTR targeted therapy for cystic fibrosis (CF) patients who carry class III/IV mutations (example G551D). In combination with corrector GLPG2222, this potentiator will also be developed for patients affected by the F508del mutation, the most prevalent mutation in CF patients. This achievement triggers a milestone payment of $10 million from AbbVie. The aim of the Phase 1 study is to evaluate the safety, tolerability and pharmacokinetics of oral single and multiple ascending doses of GLPG1837. The randomized, double-blind, placebo-controlled, single center study is being conducted in at least 40 healthy volunteers in Belgium. In the first part of the study, single ascending doses will be evaluated. In the second part, the new compound will be administered daily for 14 days. Topline results from this Phase 1 study with GLPG1837 are expected in the second half of 2015.

Galapagos Regains Full Rights to GPR84 inhibitor GLPG1205

Galapagos NV announced it has agreed with Janssen Pharmaceutica NV that Galapagos will regain full and unencumbered rights to the entire GPR84 program going forward, which includes the inhibitor GLPG1205 and its backup compound GLPG2196. GLPG1205 ('1205), works on GPR84, a novel mechanism of action developed by Galapagos for Inflammatory Bowel Diseases (IBD). Earlier 2014, Galapagos presented compelling pre-clinical evidence for GPR84 playing a key role in IBD pathology. The discovery of a selective antagonist of GPR84 led to GLPG1205, which shows strong efficacy in relevant pre-clinical models for IBD. Galapagos disclosed last year that '1205 showed good safety, target engagement, and favorable drug-like properties in Phase 1 studies in healthy volunteers. Galapagos plans to initiate Phase 2 trial patient recruitment before year end 2014.

Galapagos NV Announces First Pre-Clinical Candidate Corrector GLPG2222 for Clinical Development in Cystic Fibrosis (CF) Program

Galapagos NV announced that it nominated a first pre-clinical candidate corrector GLPG2222 for clinical development in its cystic fibrosis (CF) program. This corrector, in combination with GLPG1837, forms the core of Galapagos' future combination therapy for the most common mutation in cystic fibrosis. The Galapagos combination has shown higher efficacy in pre-clinical studies than other therapies currently under clinical development. Identification of novel, potent, and efficacious corrector candidates is part of building a triple combination therapy with Galapagos' potentiator GLPG1837, currently entering Phase 1 safety studies. Galapagos and AbbVie have developed multiple, novel correctors that in triple combination with GLPG1837, show >40% restoration of healthy (WT CFTR) activity in cells derived from CF patients with the delF508 mutation. Furthermore, the Galapagos-AbbVie corrector series compounds show good drug-like properties, which support further pre-clinical development. From these series, Galapagos selected a first pre-clinical candidate, the first corrector building block which together with potentiator GLPG1837, forms a solid basis for future triple combination developments. Galapagos is entering Phase 1 with GLPG1837 in December 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GLPG:NA €15.04 EUR +0.01

GLPG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GLPG.
View Industry Companies

Industry Analysis


Industry Average

Valuation GLPG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.5x
Price/Book 1.7x
Price/Cash Flow 7.4x
TEV/Sales 1.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALAPAGOS NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at